With the help of the data and tweets given, can you forecast whether the closing price of $gild will climb or drop at 2017-01-26? Please state either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-01-11,2.4,2.4,-1.0,-1.7,-1.7,2.0,0.7,0.5,0.7,0.2,-0.1
2017-01-12,0.2,0.4,-0.6,-0.6,-0.6,1.8,1.4,1.0,1.2,0.8,0.4
2017-01-13,0.8,1.0,-0.1,-0.4,-0.4,1.6,1.9,1.3,1.4,1.3,0.8
2017-01-17,1.4,1.4,-0.3,-1.6,-1.6,2.1,3.6,2.8,2.8,2.9,2.4
2017-01-18,0.2,0.5,-0.9,0.3,0.3,1.0,3.0,2.3,2.4,2.6,2.1
2017-01-19,0.3,1.0,-0.5,-0.8,-0.8,1.2,3.1,2.9,3.0,3.3,2.9
2017-01-20,1.4,1.4,-0.6,-0.8,-0.8,1.3,3.2,3.6,3.6,3.9,3.7
2017-01-23,0.3,0.8,-0.6,-0.5,-0.5,1.1,3.0,3.9,3.8,4.1,4.1
2017-01-24,0.5,1.0,-0.7,-0.6,-0.6,1.3,2.9,4.5,4.2,4.4,4.7
2017-01-25,-1.5,0.6,-1.7,2.4,2.4,-1.1,0.1,1.8,1.7,1.9,2.2

2017-01-11: rt AT_USER over $22m in grants from gilead to study three areas of #hiv cure research  $gild|rt AT_USER $gild told analysts at mtg today they might separate out hcv and/or hiv product guidance for 201
2017-01-12: added to $adnt today at close and i'll be stalkin any weakness in biotech from overreaction to trump $gild $celg $ions $agn &amp; several others|commented on will 2017 be different for gilead sciences
2017-01-13: AT_USER AT_USER your opinion on $gild. it is now creating a base at $73. is it worth buying, what is the cyclicality for biotech?|do you know that #book value for $gild is $12.76 |the threats and oppo
2017-01-14: rt AT_USER AT_USER nash pipeline.   nowhere complete but good one to start $agn $icpt $gild $cnat $gnftf $ibb $ccxi |rt AT_USER AT_USER nash pipeline.   nowhere complete but good one to start $agn $ic
2017-01-15: ok. twitter it is. sshh. don't tell anybody. ha $vrx $agn $myl $ko $pep $twtr $aapl $amzn $googl $gild $hlf $iep $azn $dis $sgen $ipxl $qure|must read: top trading &amp; investment resources. link:  $
2017-01-16: rt AT_USER 20 cheapest stocks in $spx on p/e basis, but are they cheap vs their 10y historical median valuations? $endp $gm $mnk $m¡­|commented on gilead goal 2018 - changing the conversation  $gild|2
2017-01-17: AT_USER AT_USER AT_USER $gild rsv compound is a fusion rsv inhibitor as well. expect similar data.|AT_USER AT_USER do these data have long term implications for the co? probably not, w/ likely superio
2017-01-18: rt AT_USER govt should buy $gild at premium. would ¡ý hep c drug costs per pt by 63% mark trusheim and i explain AT_USER op-ed |rehmann capital advisory group has $1,185,000 position in gilead science
2017-01-19: botty investors llc has $1,582,000 position in gilead sciences inc. $gild |will AT_USER inaugural speech cause $ibb $xbi $celg $amgn $clvs $biib $uthr $gild to:|rt AT_USER cure your portfolio with gil
2017-01-20: galapagos $glpg /gilead $gild:long-term extension of filgotinib phase 3 trials to be started next month (3y f-up) |$googl #seo #searchengineoptimization #bots #like #retweeting from  $gild $qcom $f #f
2017-01-21: rt AT_USER gilead quiet on deals, but talks up pipeline at jpm  #jpm $gild |rt AT_USER gilead quiet on deals, but talks up pipeline at jpm  #jpm $gild |rt AT_USER gilead quiet on deals, but talks up p
2017-01-22: i have 1 friend who thinks fundamentals is the answer to trading. he is still holding $gild because it's "the best business in the industry|rt AT_USER  $spy, $qqq, $iwm, $nflx, $bmy, $gild, $qcom|$gil
2017-01-23: AT_USER $gild that current value trap has a bite|jerome dodson adds to #gileadsciences position. read more:  $gild|rt AT_USER buy gilead's hiv franchise and get the rest of the company for free  $gild
2017-01-24: AT_USER AT_USER ty for our discussion of mark trusheim and my idea the govt buy $gild  AT_USER |rt AT_USER AT_USER current cfo at $exel is from $gild|better buy: biogen inc. vs. gilead sciences inc. $
2017-01-25: $gild analysts prediction of $7.2b revenues are way off imo.|$gild it's going to beat last quarter's $7.5b in revenues - even if hcv falls off another $250m.|$gild:us citi thinks gilead (gild) "still 
Answer:
date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-01-11,2.4,2.4,-1.0,-1.7,-1.7,2.0,0.7,0.5,0.7,0.2,-0.1
2017-01-12,0.2,0.4,-0.6,-0.6,-0.6,1.8,1.4,1.0,1.2,0.8,0.4
2017-01-13,0.8,1.0,-0.1,-0.4,-0.4,1.6,1.9,1.3,1.4,1.3,0.8
2017-01-17,1.4,1.4,-0.3,-1.6,-1.6,2.1,3.6,2.8,2.8,2.9,2.4
2017-01-18,0.2,0.5,-0.9,0.3,0.3,1.0,3.0,2.3,2.4,2.6,2.1
2017-01-19,0.3,1.0,-0.5,-0.8,-0.8,1.2,3.1,2.9,3.0,3.3,2.9
2017-01-20,1.4,1.4,-0.6,-0.8,-0.8,1.3,3.2,3.6,3.6,3.9,3.7
2017-01-23,0.3,0.8,-0.6,-0.5,-0.5,1.1,3.0,3.9,3.8,4.1,4.1
2017-01-24,0.5,1.0,-0.7,-0.6,-0.6,1.3,2.9,4.5,4.2,4.4,4.7
2017-01-25,-1.5,0.6,-1.7,2.4,2.4,-1.1,0.1,1.8,1.7,1.9,2.2

2017-01-11: rt AT_USER over $22m in grants from gilead to study three areas of #hiv cure research  $gild|rt AT_USER $gild told analysts at mtg today they might separate out hcv and/or hiv product guidance for 201
2017-01-12: added to $adnt today at close and i'll be stalkin any weakness in biotech from overreaction to trump $gild $celg $ions $agn &amp; several others|commented on will 2017 be different for gilead sciences
2017-01-13: AT_USER AT_USER your opinion on $gild. it is now creating a base at $73. is it worth buying, what is the cyclicality for biotech?|do you know that #book value for $gild is $12.76 |the threats and oppo
2017-01-14: rt AT_USER AT_USER nash pipeline.   nowhere complete but good one to start $agn $icpt $gild $cnat $gnftf $ibb $ccxi |rt AT_USER AT_USER nash pipeline.   nowhere complete but good one to start $agn $ic
2017-01-15: ok. twitter it is. sshh. don't tell anybody. ha $vrx $agn $myl $ko $pep $twtr $aapl $amzn $googl $gild $hlf $iep $azn $dis $sgen $ipxl $qure|must read: top trading &amp; investment resources. link:  $
2017-01-16: rt AT_USER 20 cheapest stocks in $spx on p/e basis, but are they cheap vs their 10y historical median valuations? $endp $gm $mnk $m¡­|commented on gilead goal 2018 - changing the conversation  $gild|2
2017-01-17: AT_USER AT_USER AT_USER $gild rsv compound is a fusion rsv inhibitor as well. expect similar data.|AT_USER AT_USER do these data have long term implications for the co? probably not, w/ likely superio
2017-01-18: rt AT_USER govt should buy $gild at premium. would ¡ý hep c drug costs per pt by 63% mark trusheim and i explain AT_USER op-ed |rehmann capital advisory group has $1,185,000 position in gilead science
2017-01-19: botty investors llc has $1,582,000 position in gilead sciences inc. $gild |will AT_USER inaugural speech cause $ibb $xbi $celg $amgn $clvs $biib $uthr $gild to:|rt AT_USER cure your portfolio with gil
2017-01-20: galapagos $glpg /gilead $gild:long-term extension of filgotinib phase 3 trials to be started next month (3y f-up) |$googl #seo #searchengineoptimization #bots #like #retweeting from  $gild $qcom $f #f
2017-01-21: rt AT_USER gilead quiet on deals, but talks up pipeline at jpm  #jpm $gild |rt AT_USER gilead quiet on deals, but talks up pipeline at jpm  #jpm $gild |rt AT_USER gilead quiet on deals, but talks up p
2017-01-22: i have 1 friend who thinks fundamentals is the answer to trading. he is still holding $gild because it's "the best business in the industry|rt AT_USER  $spy, $qqq, $iwm, $nflx, $bmy, $gild, $qcom|$gil
2017-01-23: AT_USER $gild that current value trap has a bite|jerome dodson adds to #gileadsciences position. read more:  $gild|rt AT_USER buy gilead's hiv franchise and get the rest of the company for free  $gild
2017-01-24: AT_USER AT_USER ty for our discussion of mark trusheim and my idea the govt buy $gild  AT_USER |rt AT_USER AT_USER current cfo at $exel is from $gild|better buy: biogen inc. vs. gilead sciences inc. $
2017-01-25: $gild analysts prediction of $7.2b revenues are way off imo.|$gild it's going to beat last quarter's $7.5b in revenues - even if hcv falls off another $250m.|$gild:us citi thinks gilead (gild) "still 